Ownership and insider activity for Intellia Therapeutics, Inc. (NTLA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema.
Price
| Price | $11.49 |
| Market Cap | $1.6B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-20 | LEONARD JOHN M | S-Sale | 19,890 | $251K |
| 2026-08-21 | LEONARD JOHN M | S-Sale | 2,785 | $36K |
| 2026-07-22 | Dulac Edward J III | S-Sale | 8,111 | $91K |
| 2026-07-01 | Dube Michael P | S-Sale | 2,641 | $44K |
| 2026-07-02 | Dulac Edward J III | S-Sale | 4,677 | $84K |
| 2026-06-09 | Verwiel Frank | A-Award | 9,200 | |
| 2026-06-09 | Verwiel Frank | A-Award | 13,300 | $171K |
| 2026-06-09 | Keresty Georgia | A-Award | 9,200 | |
| 2026-06-09 | Keresty Georgia | A-Award | 13,300 | $171K |
| 2026-06-09 | GOODMAN JESSE | A-Award | 9,200 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $273.1M | $340.7M | $58.9M | $57.2M | $160.0M | $123.4M | $523.5M | $226.7M | $189.2M | $155.5M |
| Short-term Investments | 0 | 0 | $255.2M | $222.5M | $437.4M | $625.3M | $669.1M | $685.5M | $412.3M | $294.4M |
| Receivables | $6.5M | $10.5M | $7.5M | $4.6M | $2.1M | $2.0M | $3.8M | $36.5M | $8.5M | $9.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $281.3M | $354.8M | $325.0M | $289.5M | $616.5M | $769.3M | $1.22B | $998.3M | $639.9M | $527.7M |
| Property, Plant & Equipment | $10.6M | $15.3M | $17.1M | $37.1M | $55.1M | $100.1M | $161.0M | $148.1M | $246.7M | $123.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $299.0M | $376.2M | $347.3M | $334.3M | $676.3M | $1.29B | $1.52B | $1.30B | $1.19B | $842.1M |
| Accounts Payable | $4.7M | $2.2M | $2.7M | $3.9M | $10.5M | $9.7M | $5.2M | $7.5M | $14.6M | $20.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $30.7M | $31.4M | $40.6M | $35.6M | $64.3M | $125.8M | $126.6M | $115.2M | $110.9M | $103.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $66.8M |
| Total Liabilities | $89.1M | $75.6M | $69.4M | $64.4M | $149.2M | $254.2M | $284.5M | $250.8M | $319.1M | $170.7M |
| Retained Earnings | -$53.6M | -$121.1M | -$201.0M | -$300.9M | -$435.1M | -$703.0M | -$1.18B | -$1.66B | -$2.18B | -$2.59B |
| Total Equity | $209.8M | $300.6M | $277.9M | $269.9M | $527.1M | $1.04B | $1.24B | $1.05B | $872.0M | $671.4M |
| Total Debt | 0 | 0 | 0 | $18.4M | $39.3M | $74.0M | $130.7M | $115.3M | $210.2M | $93.3M |
| Net Debt | -$273.1M | -$340.7M | -$314.1M | -$261.4M | -$558.1M | -$674.7M | -$1.06B | -$796.9M | -$391.3M | -$356.6M |
| Working Capital | $250.6M | $323.5M | $284.4M | $253.8M | $552.3M | $643.5M | $1.09B | $883.1M | $529.0M | $423.8M |
Financial Health
| Debt / Equity | 0.10 |
| Current Ratio | 6.65 |
Profitability
| Return on Equity | -57.79% |
| Return on Invested Capital | -52.86% |
| Return on Assets | -46.66% |
| Gross Margin | -46.48% |
| Operating Margin | -711.66% |
| Net Margin | -672.16% |
Related companies: BCRX · BHVN · IMNM · PHVS · STOK · SYRE · UPB
Explore sector: Healthcare · Biotechnology
More sections of NTLA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks